干扰素-α1b与病毒唑治疗小儿病毒性肺炎的疗效对比研究  

Comparative effectiveness of interferon-α1b and ribavirin on viral pneumonia in children

作　　者：梁宽[1] 彭林强[1] 李园[1] 马春利[1] 薛满 

机构地区：[1]陕西省宝鸡市人民医院儿科,宝鸡721000

出　　处：《广西医科大学学报》2017年第1期69-73,共5页Journal of Guangxi Medical University

摘　　要：目的:对比分析干扰素-α1b(INF-α1b)和病毒唑治疗小儿病毒性肺炎的临床疗效。方法 :选择2014年6月至2016年6月陕西省宝鸡市人民医院儿科收治的病毒性肺炎患儿120例,按随机数字表法分为观察组和对照组,每组60例。两组均予以常规治疗,观察组和对照组分别加用INF-α1b和病毒唑治疗,对比两组的临床疗效、T淋巴细胞亚群变化、血清炎症因子的变化及不良反应发生情况。结果:观察组的治愈率和总有效率分别为50.00%、93.33%,显著高于对照组的26.67%、63.33%(P<0.05)。观察组发热、憋喘、肺啰音、咳嗽等症状消失时间均显著短于对照组(P<0.05)。治疗后,观察组T淋巴细胞亚群CD4^+、CD8^+水平及CD4^+/CD8^+比值均显著高于对照组(P<0.05),血清白介素(IL)-6、IL-8及肿瘤坏死因子-α(TNF-α)水平均显著低于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:INF-α1b治疗小儿病毒性肺炎较病毒唑更为安全、有效,且能改善机体免疫功能并减轻炎症反应,值得临床推广应用。Objective： To compare the clinical efficacy of interferon-α1b （INF-α1b） and ribavirin for the treatment of children with viral pneumonia. Methods： 120 children with viral pneumonia treated in our hospital from June 2014 to June 2016 were selected and randomly divided into an observation group and a control group, with 60 cases in each group. Both groups of patients received routine therapy, and the patients in the observation group were added with INF-α1b, while those in the control group were added with ribavirin. The curative effect, percentages of T lymphocyte subsets, the serum levels of inflammatory cytokines and the incidence of adverse reactions were compared. Results： The curative rate and total response rate in the observation group were 50.00 % and 93.33% respectively, which were significantly higher than those in the control group （26.67% and 63.33%） （ P 〈0.05）. The duration of clinical symptoms including fever, asthma, lung rale and cough in the observation group was significantly shorter than that in the control group （ P 〈0.05）. After treatment, the CD4＋ , CD8＋ T-cells counts and CD4＋/CD8＋ ratio were higher, while the serum interleukin （IL）-6, IL-8 and tumor necrosis factor-α（TNF-α） levels were lower in the observation group than those in the control group （ P %0.05）. There was no statistical difference in the incidence of adverse reactions between the two groups （ P〉0.05）. Conclusion： INF-α1b was safe and more effective than ribavirin in treating viral pneumonia in children. It could improve patients immune function and attenuate inflammatory response as well.

关 键 词：病毒性肺炎 小儿 干扰素-Α1B 病毒唑 临床疗效 

分 类 号：R272[医药卫生—中医儿科学]